骨肉瘤患者微小RNA124的表达水平及其对预后的预测价值
详细信息    查看全文 | 推荐本文 |
  • 作者:陈汉文 ; 高书明 ; 辛大森 ; 程才 ; 李勇
  • 关键词:骨肉瘤 ; 微小RNA124 ; 表达 ; 预后
  • 中文刊名:TDYX
  • 英文刊名:Modern Medical Journal
  • 机构:沧州市中心医院骨一科;
  • 出版日期:2019-04-25
  • 出版单位:现代医学
  • 年:2019
  • 期:v.47;No.310
  • 基金:2017年沧州市科学技术研究与发展指导计划项目(172302139)
  • 语种:中文;
  • 页:TDYX201904006
  • 页数:4
  • CN:04
  • ISSN:32-1659/R
  • 分类号:28-31
摘要
目的:探究骨肉瘤患者微小RNA124(miR-124)的表达水平及其对预后的预测价值。方法:选择在我院手术治疗的86例骨肉瘤患者,根据miR-124水平分为高水平组(42例)和低水平组(44例),并选择20例新鲜骨折的患者作为对照组;比较3组患者miR-124的表达水平,分析高水平与低水平组患者临床资料及预后的差异,以及影响患者预后的危险因素。结果:低水平组患者的临床分期ⅡB/Ⅲ期、远处转移以及化疗效果不佳的比例显著高于高水平组(P <0. 05)。骨肉瘤患者miR-124表达量显著低于对照组(P <0. 05);骨肉瘤患者非肿瘤组织中miR-124表达量明显高于肿瘤组织(P <0. 05)。高水平组患者的死亡风险明显低于低水平组(HR=0. 463,P=0. 029)。Cox回归分析显示,miR-124低表达是患者预后不佳的独立危险因素(HR=2. 145,P=0. 044),化疗有效是保护因素(HR=0. 495,P=0. 047)。结论:骨肉瘤患者miR-124表达水平较低,miR-124低表达水平患者的预后较差;化疗有效是骨肉瘤患者术后预后的保护因素,miR-124低表达是独立危险因素。
        
引文
[1]牛晓辉.经典型骨肉瘤临床诊疗专家共识的解读[J].临床肿瘤学杂志,2012,17(10):934-945.
    [2] NISHIDA-AOKI N,OCHIYA T. Interactions between cancer cells and normal cells via miRNAs in extracellular vesicles[J]. Cell Mol Life Sci,2015,72(10):1849-1861.
    [3]WANG H. Predicting cancer-related MiRNAs using expression profiles in tumor tissue[J]. Curr Pharm Biotechnol,2014,15(5):438-444.
    [4]HAN G,WANG Y,BI W,et al. MicroRNA-124 functions as a tumor suppressor and indicates prognosis in human osteosarcoma[J]. Exp Ther Med,2015,9(3):679-684.
    [5]舒锦,袁犁,刘兴明,等. miR-124在卵巢癌中的表达及其对卵巢癌细胞生物学行为的影响[J].肿瘤,2014,34(5):430-436.
    [6]刘锋,谢黎明,张志伟,等. miR-124在胃癌中的表达及临床意义[J].中国癌症杂志,2016,26(3):215-220.
    [7]中国抗癌协会肉瘤专业委员会.经典型骨肉瘤临床诊疗专家共识[J].临床肿瘤学杂志,2012,17(10):931-933.
    [8]郭征.我国骨肉瘤治疗的现状与问题及发展方向[J].中国骨与关节杂志,2015,4(5):338-342.
    [9]牛晓辉. 2017版NCCN《骨肿瘤临床实践指南》更新与解读[J].中华外科杂志,2017,55(1):41-43.
    [10]CONG C,WANG W,TIAN J,et al. Identification of serum miR-124 as a biomarker for diagnosis and prognosis in osteosarcoma[J]. Cancer Biomark,2018,21(2):449-454.
    [11]孟凡龙,王伟,荚卫东.循环miRNA与肝癌的研究进展[J].中华外科杂志,2014,52(2):146-148.
    [12]ROMERO-CORDOBA S L,SALIDO-GUADARRAMA I,RODRIGUEZ-DORANTES M,et al. miRNA biogenesis:biological impact in the development of cancer[J]. Cancer Biol Ther,2014,15(11):1444-1455.
    [13]FENG T,XU D,TU C,et al. MiR-124 inhibits cell proliferation in breast cancer through downregulation of CDK4[J].Tumour Biol,2015,36(8):5987-5997.
    [14]CHENG Y,LI Y,NIAN Y,et al. STAT3 is involved in miR-124-mediated suppressive effects on esophageal cancer cells[J]. BMC Cancer,2015,15:306.
    [15]ARABKHERADMAND A,SAFARI A,SEIFOLESLAMI M,et al. Down-regulated microRNA-124 expression as predictive biomarker and its prognostic significance with clinicopathological features in breast cancer patients[J]. Diagn Pathol,2015,10:178.
    [16]TANIGUCHI K,SUGITO N,KUMAZAKI M,et al. MicroRNA-124 inhibits cancer cell growth through PTB1/PKM1/PKM2feedback cascade in colorectal cancer[J]. Cancer Lett,2015,363(1):17-27.
    [17]ZHANG J,LU Y,YUE X,et al. MiR-124 suppresses growth of human colorectal cancer by inhibiting STAT3[J]. PLo S One,2013,8(8):e70300.
    [18]SHI X B,MA A H,XUE L,et al. miR-124 and androgen receptor signaling inhibitors repress prostate cancer growth by downregulating androgen receptor splice variants,EZH2,and Src[J]. Cancer Res,2015,75(24):5309-5317.
    [19]WANG P,CHEN L,ZHANG J,et al. Methylation-mediated silencing of the miR-124 genes facilitates pancreatic cancer progression and metastasis by targeting Rac1[J]. Oncogene,2014,33(4):514-524.
    [20]JINUSHI T,SHIBAYAMA Y,KINOSHITA I,et al. Low expression levels of microRNA-124-5p correlated with poor prognosis in colorectal cancer via targeting of SMC4[J].Cancer Med,2014,3(6):1544-1552.
    [21]LU Y,YUE X,CUI Y,et al. MicroRNA-124 suppresses growth of human hepatocellular carcinoma by targeting STAT3[J].Biochem Biophys Res Commun,2013,441(4):873-879.
    [22]OSAKI M,OKADA F,OCHIYA T. miRNA therapy targeting cancer stem cells:a new paradigm for cancer treatment and prevention of tumor recurrence[J]. Ther Deliv,2015,6(3):323-337.

© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号

地址:北京市海淀区学院路29号 邮编:100083

电话:办公室:(+86 10)66554848;文献借阅、咨询服务、科技查新:66554700